Prospective Multicenter Observational Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke; Thromboembolism; Thrombosis
- Focus Therapeutic Use
- Acronyms NEURO-XAR
- Sponsors Bayer
- 13 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov.
- 17 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 13 Jun 2014 Planned end date changed from 1 Jun 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov